Merck & Co., Inc. (BVMF:MRCK34)

Market Cap	1.08T
Revenue (ttm)	346.63B
Net Income (ttm)	89.39B
Shares Out	n/a
EPS (ttm)	35.34
PE Ratio	12.03
Forward PE	8.81
Dividend	1.58 (2.82%)
Ex-Dividend Date	Sep 12, 2025

Volume	14
Average Volume	3,029
Open	56.91
Previous Close	57.48
Day's Range	55.93 - 56.91
52-Week Range	51.60 - 82.12
Beta	0.38
RSI	35.14
Earnings Date	Oct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: MRCK34

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD